Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer leaf node


URI

https://openalex.org/T12829

Label

Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer

Description

This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.

Implementation

@prefix oasubfields: <https://openalex.org/subfields/> .
@prefix openalex: <https://lambdamusic.github.io/openalex-hacks/ontology/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://openalex.org/T12829> a skos:Concept ;
    rdfs:label "Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer"@en ;
    rdfs:isDefinedBy openalex: ;
    owl:sameAs <https://en.wikipedia.org/wiki/Palbociclib#Breast_cancer_therapy>,
        <https://openalex.org/T12829> ;
    skos:broader oasubfields:2740 ;
    skos:definition "This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers."@en ;
    skos:inScheme openalex: ;
    skos:prefLabel "Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer"@en ;
    openalex:cited_by_count 166179 ;
    openalex:works_count 24085 .